Pharma Services Market — 2025 Update

Synthesis of three investment banking sector reports: Houlihan Lokey’s Pharma Services and Technology 2025 Market Update (released ~October 2025), Bourne Partners’ Pharma Services Market Update: Post-2Q25 Update (August 2025), and Bourne Partners’ Pharma Commercialization and Market Access: Perspectives and Research (July 2025).

Market Overview

Key structural drivers (2025-2030 outlook):

Increasing complexity of innovative products (biologics, gene therapies, precision medicines for rare/orphan indications) driving sustained demand for specialized outsourced capabilities
Growing use of real-world data (RWD), AI-enabled tools, and omnichannel engagement requiring specialized platform investment that pharma companies cannot cost-effectively build in-house
$125 billion in expected annual net sales from new drug brand launches over the next five years (Bourne Partners estimate, July 2025) — up materially from ~$95B over the prior five years, excluding COVID-19 products
Biotech funding rebounding: Q4-2024 TTM investment up 43% YoY; rate cuts supporting capital access
Phase II/III clinical trial volumes healthy following post-COVID normalization

Policy Environment

Inflation Reduction Act (IRA) — Ongoing Impact

The IRA of 2022 continues to reshape commercialization strategy:

Medicare drug price negotiation creates pressure on high-volume commercial products
Manufacturers are responding by focusing investment on orphan/rare disease indications (protected from IRA negotiations), biologics (harder to genericize post-LOE), and products with clear differentiated clinical value
Market access resources being allocated earlier in drug development (Phase I/II) to generate HEOR and RWE evidence that demonstrates comparative effectiveness to payers

One Big Beautiful Bill (OBBB) Act of 2025

Signed July 2025; materially improved regulatory treatment of orphan drugs:

Under IRA, orphan drugs with a single indication were exempt from Medicare price negotiations
OBBB expanded this exemption to all orphan drugs, regardless of number of indications
Oncology drugs with multiple indications are key beneficiaries
Effect: increases incentive to pursue rare disease / orphan indications, favorable for clinical trial services, specialized hub/patient services, and medical affairs vendors

Trump Administration Policies

Most Favored Nation (MFN) pricing: Executive order directing manufacturers to align U.S. drug prices with other developed countries; relies on voluntary compliance; procedural steps delay any near-term impact. AstraZeneca and Pfizer reached specific agreements with the administration.
Tariffs on pharmaceutical imports: 100% tariff on pharma imports announced September 2025; branded drugs expected to absorb impact given high margins; generics face harder hit. Pharma companies with domestic manufacturing investments have near-term relief.
FDA dynamics: Despite high-level policy noise, FDA’s day-to-day approval activity has remained active (e.g., Dupixent approval April 2025); industry leaders characterize the working-level environment as functional.
HHS restructuring (RIFs): HHS workforce reductions create some operational uncertainty but have not materially slowed approvals.

Commercialization Services — Key Themes (Bourne Partners, July 2025)

Growing Need for Earlier Market Access Investment

With IRA pressure on commercial-stage pricing, payers increasingly require differentiated clinical and economic evidence at launch. Manufacturers are investing in:

HEOR / RWE programs beginning in Phase I/II (rather than post-approval)
Market access strategy earlier in the lifecycle to understand formulary positioning and payer objections before NDA submission
Medical affairs as an increasingly strategic (not just scientific) function — moving from publication planning to real-world evidence generation and field medical engagement

Patient Support & Hub Services

Patient services remain a critical commercialization investment with tailwinds:

Hub services demand is growing as specialty drug complexity and reimbursement hurdles intensify
Outsourcing rates across all service lines projected to increase as payer utilization management grows more burdensome
Patient support vendors that can demonstrate net revenue impact (conversion rates, speed to therapy, adherence lift) are commanding premium positioning vs. activity-based vendors

Medical Affairs Rising

Medical affairs is evolving from a cost center into a value-generation function:

Generating RWE and HEOR studies for payer communications
Supporting HCP engagement through MSLs and advisory boards
Driving publication strategy to establish comparative clinical positioning
Bourne Partners sees medical affairs as a strong M&A target sector in 2025-2026

M&A and Valuation Environment

Public Market Valuation Benchmarks (Houlihan Lokey, October 2025)

Sector	EV/NTM EBITDA
Tech-Enabled Pharma Services	19.2x
CROs	18.0x
Total Pharma Services Index	16.7x
CDMOs	16.7x
S&P 500	15.7x
Distributors	14.7x

Tech-enabled pharma services companies command the highest multiples, reflecting recurring revenue, data network effects, and embedded workflow advantages. Pure-play distributors trade at the lowest multiples despite strong equity performance (+85.3% over 24 months through October 2025).

PE Activity

2025 has seen a resurgence in scaled platform transactions as positive LTM performance catalyzes PE exits for long-tenured assets
Strong lender support across pharma services; financing terms favorable for well-underwritten deals
Key 2025 transactions: Thermo Fisher acquisition of Clario ($8.875B); Bain/Kohlberg/Mubadala investment in PCI Pharma Services ($10B valuation); THL acquisition of Headlands Research from KKR; Klick Group growth investment from Linden Capital Partners and GIC; Mercalis/PharmaCord merger/rebrand

Key Observations for Hub/Commercialization Vendors

From the Houlihan Lokey and Bourne Partners reports:

Strong pipeline of quality assets coming to market; 2026 expected to see accelerated M&A activity
Vendors with integrated data platforms, AI capabilities, or multi-service bundling command premium multiples (19x+)
Point-solution vendors in commoditizing categories (e.g., basic copay administration without data differentiation) face multiple compression
Commercialization services (market access, patient support, medical affairs, agency) are among the most active M&A sub-sectors within pharma services

Biotech Pipeline and New Drug Activity

FDA approvals and trial volumes (2024-2025):

50 novel FDA approvals in 2024 (consistent with 5-year trend of 45-55/year)
Phase II/III clinical trial volumes at or above 2022 levels following post-COVID-19 normalization
Emerging biopharma now originates and launches a majority of novel drugs; large pharma increasingly acquires or licenses biotech assets post-Phase II

Biotech funding (2024 recovery):

TTM biotech funding (Q4-2024): $134B — up significantly from 2022-2023 troughs ($57-68B)
IPO and follow-on activity recovering; private investment rebounding
Pipeline drugs in development: 3,728 as of 2024 (vs. 3,456 in 2020)

Implications for Pharma Services Vendors

Service Category	Tailwind	Headwind
Hub / Patient Services	Specialty drug complexity increasing; more launches; OBBB protecting orphan programs	IRA price pressure on commercial products may reduce net revenue per patient justifying hub spend
Market Access Consulting	Earlier-stage engagement required; HEOR/RWE demand growing	Policy uncertainty makes payer strategy harder to lock in pre-launch
Medical Affairs	Growing strategic importance; multiple indications per drug increasing	Tariff/HHS uncertainty creating sponsor budget caution
CROs / Clinical Research	Phase II/III volumes rebounding; orphan drug focus driving specialized trial needs	2022-2024 volume trough left backlogs; some capacity consolidation underway
CDMOs	Biologics/gene therapy manufacturing demand growing	Tariff and domestic manufacturing pressure; GLP-1 capacity overhang
Tech-Enabled Services	Premium valuations; AI investment accelerating	Point solutions face commoditization risk without data moat